Clinical trial
A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
NCT01186328 is registered in ClinicalTrials.gov with Therapeutic Advances in Childhood Leukemia Consortium as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 24, 2010
- Completion date
- January 10, 2012
- Enrollment
- 6 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
leukemia, lymphoblastic, acute, leukemia, lymphoblastic, acute, t cell, lymphoblastic leukemia, acute, lymphoblastic leukemia, acute, childhood